These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Benign (BI-RADS 2) lesions in breast MRI.
    Author: Spick C, Szolar DH, Tillich M, Reittner P, Preidler KW, Baltzer PA.
    Journal: Clin Radiol; 2015 Apr; 70(4):395-9. PubMed ID: 25649442.
    Abstract:
    AIM: To assess the frequency of malignancy in lesions characterized as benign [Breast Imaging-Reporting and Data System (BI-RADS) 2] on breast MRI. MATERIALS AND METHODS: In this institutional review board-approved retrospective single-centre study, 1265 consecutive patients (mean age 50 ± 13 years), undergoing dynamic contrast-enhanced MRI (1.5 T) of the breast during a 6 year time period, were eligible. This study investigated the MRI characteristics and frequency of malignancy in 192 of these patients with breast lesions classified as BI-RADS 2. Examinations were read during clinical practice and classified according to the MRI BI-RADS lexicon. Based on the patient's and referring physician's preferences, lesions were either histopathologically verified or were subjected to both clinical and imaging follow-up of at least 2 years (range 2-9 years). Descriptive statistical metrics were calculated. RESULTS: According to the standard of reference, 0 of 192 (0%) lesions classified as BI-RADS 2 were malignant. Histopathology was available in 67 (34.9%) lesions and revealed benign findings exclusively. The remaining 125 (65.1%) lesions did not exhibit changes during the follow-up period and were, therefore, considered negative for malignancy. CONCLUSIONS: The frequency of malignancy in breast lesions classified as BI-RADS 2 is zero. As a consequence, breast biopsies are unnecessary in these cases.
    [Abstract] [Full Text] [Related] [New Search]